12 results on '"Chiu, Vi Kien"'
Search Results
2. Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
3. Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
4. Actionable genomic biomarkers in a low socioeconomic status (SES) population with gastrointestinal (GI) cancers.
5. First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
6. Effect of tumor progression on colon cancer stem cell plasticity.
7. Disparities in treatment-related financial burden and recurrence in a diverse sample of colorectal cancer survivors.
8. Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.
9. The impact of ImmunoPrecision in small bowel adenocarcinoma.
10. Integrated survival analysis.
11. A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).
12. System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.